Greetings and welcome to the NeoGenomics’ Fourth Quarter and Full Year 2016 Financial Results Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Doug VanOort, Chairman and CEO. Thank you, Mr. VanOort, you may begin.

Thank you, Tim. Good morning, everyone. I would like to welcome everyone to NeoGenomics’ fourth quarter and full year 2016 conference call and introduce you first to the NeoGenomics team that’s with us here today. Joining me in our Fort Myers headquarters is Steve Jones, our Executive Vice President; George Cardoza, our Senior Vice President and Chief Financial Officer; Fred Weidig, our Comptroller and Principal Accounting Officer; Jessica King, our Manager of SEC Reporting; Rob Shovlin, President of our Clinical Services Division; and Steve Ross, our Vice President and Chief Information Officer. Dr. Maher Albitar, our Senior Vice President, Chief Medical Officer and Director of R&D is joining us from our Aliso Viejo Lab in California. Before we begin our prepared remarks, Steve Jones will read the standard language about the forward-looking statements.

This conference call may contain forward-looking statements, which represent our current expectations and beliefs about our operations, performance, financial condition and growth opportunities. Any statements made on this call that are not statements of historical fact are forward-looking statements. These statements by their nature, involve substantial risks and uncertainties, certain of which are beyond our control. Should one or more of these risks or uncertainties materialize or should the underlying assumptions prove incorrect, actual outcomes and results could differ materially from those indicated in the forward-looking statements. Any forward-looking statement speaks only as of today and we undertake no obligation to update any such statements to reflect events or circumstances after today.

Thank you, Steve. In this morning’s call, I will put 2016 into context, comment on fourth quarter performance, update you on the status of the Clarient integration and conclude with a look forward to growth and value creation opportunities for our company this year and over the next few years. 2016 was clearly a transformational year for NeoGenomics. We more than doubled the size of the company with 2016 revenue of $244 million compared to $99 million in 2015. We significantly deepened our oncology testing menu and capabilities and now have a leading position in many geographic areas and in every key testing discipline for oncology. We added an exciting new growth business serving the pharmaceutical industry and are now positioned as an emerging lab services leader for immunooncology. And importantly, our adjusted EBITDA more than tripled to almost $35 million from about $10 million in 2015. In addition, we leveraged our $21 million in cash flow from operations and improved financial position to redeem more than half of the Series A preferred stock we issued to GE in connection with the acquisition. We ended the year with a strong new bank syndicate and with borrowing capacity and financial flexibility to pursue our growth strategies. Now, just 13 months after our acquisition of Clarient, we have successfully migrated all of the approximately 2,500 Clarient clients. And today, every single one of our clients is using a common service offering, a common laboratory information system and a common billing system. With this migration effort completed, we can now build on our strengths in a common, efficient and more effective manner and unlock meaningful synergies. Integrating an equally sized laboratory into our operations has been a challenging and complex undertaking that could have stretched into a number of years rather than a…

Thanks, Doug. Before we open it up for questions, I would like to briefly touch on a few financial highlights from the quarter. We are pleased to report $60.5 million of revenue in quarter four, a 122% increase over the prior year, driven primarily by the inclusion of Clarient in the results. Approximately $53.8 million of this revenue was derived from the core clinical genetic testing business, $1.5 million from Path Logic and $5.1 million from the pharma services division. Consolidated gross margin was 45.1%, a 30 basis point increase from the 44.8% reported in Q4 2015. This increase in gross margin was driven by the 10.7% year-over-year decrease in average cost of goods sold per clinical genetic test to $192 per test. This is the lowest level we have ever reported for this metric and this is before we unlocked the additional cost synergies from having all clients on one laboratory information system and all of our Orange County, California employees in the same facility. Consolidated SG&A expense increased by $12.8 million or 73% from Q4 2015. However, as we discussed in the press release, $1.5 million of this increase was due to non-cash variable stock-based compensation and non-cash amortization of intangibles directly related to the Clarient acquisition, and an additional $3.5 million of this increase was due to a non-cash impairment charge in quarter four to write-off the remaining unamortized intangible values associated with the Path Logic acquisition and a licensing agreement. Given the reductions in cost per test and the economies of scale we achieved on the cash portion of our SG&A expenses, consolidated adjusted EBITDA increased by 178% year-over-year to $8.1 million and adjusted EBITDA margin grew by 280 basis points to 13.5%. As we discussed in the press release, we incurred $3.9 million of one-time…

Thank you. [Operator Instructions] Our first question comes from the line of Bill Bonello of Craig-Hallum. Please proceed with your question.

Good morning, guys. Couple of follow-ups here. So, the move in price or in ASP, is that 100% related to mix or are you seeing any kind of price pressure either from payers or large client bill customers?

It’s mostly mix related. It’s somewhat continued evolution of molecular and IHD testing, which is going must faster than the rest of the business and has created pressure on it. We always get a little bit of pressure from clients as time goes on, but it doesn’t really wind up being very meaningful on a sequential basis.

Okay. And then there is customers and there are customers, can you give us any greater sense of the client that said they were dissatisfied and planning on going somewhere else. I think you originally gave a client attrition estimate of like $6 million or something, I mean, are you still within that range or how big a deal is this particular client?

Yes, I would be grabbing my chest, if it was $6 million client attrition. No, so, Bill, we reported in the last call that we were – we had lost one client. We actually managed to get that client back. The client that we referred to this morning is not a large client, but every single one is sort of painful for us. I mentioned that our clients – our service is generally exceptional and we take great pains to make sure that every single client, is delighted with our service and we didn’t do as good a job in the last 3 or 4 weeks of the end of the year. And so we are focusing our full attention on this. We still want to have 100% client retention. We are still trying to do that. I think it’s possible that because we have some fragile clients that we were in danger of and got our full attention on that, but I don’t thing that will have a lot of client attrition.

Okay, that’s helpful. And then just the last question, I am curious if you have any thoughts on organic growth going forward from a volume standpoint? I mean, I guess, it’s sort of implicit in the guidance you gave, but just when might you expect to see the PD-L1 volume burst kind of run its course. And when that happens, do we see a big drop in the organic volume growth or is that sort of offset, because you have returned to more normalized operations as opposed to focusing on integration activity?

Thanks, Bill. It’s Steve. Our forecast – the midpoint of our forecast sort of implies somewhere in the order of 15% area, clinical genetic test volume growth. We don’t actually project out individual line items in our forecast, but obviously IHC testing we are expecting to continue to be outsized growth here in at least the next quarter or two. When a new therapy is approved as a first line therapy, there is always a big catch up period where everybody who hasn’t thought about that therapy looks at it with our clients and wants to test their clients to see whether that therapy would be appropriate. So we are going through a lot of that initial bulge here. Doug, I don’t know if you think differently about it thinking that in another quarter or two that will settle down the initial bulge and then we will see normal growth in PD-L1.

Yes, I think that’s right, Steve. We are pleased that we have such a strong market share we believe in PD-L1 testing and we think that this is leveragable, because we do have some clients and are only sending PD-L1 testing to us. And we can certainly leverage that situation. And I think the other thing about immunooncology is this is a growing business and growing trend and we are leaders, not only in the clinical side of PD-L1 testing, but in immunooncology generally and that relates to growth in our pharma services business as well.

Great. Thank you.

Our next question comes from the line of Amanda Murphy of William Blair. Please proceed with your questions.

Hi, good morning. I just had a follow-up actually to some of Bill’s questions. So in terms of the volume, if you put aside PD-L1 and the molecular piece, the rest of the business, I just want to make sure, I am interpreting it correctly. So the volume there, those were – are you saying those were the challenged, because the sales force was more focused on service or are you saying that because you had such high growth in PD-L1 and molecular that implicitly impacted the ability to grow on the other side of the business, I am trying to just distinguish between the two, I guess, whether PD-L1s are cannibalized to growth in anyway?

Amanda, this is Doug. The primary reason was because our salespeople were so preoccupied with client retention during the last 5 or 6 months of the year. The PD-L1 growth occurred, because we have the capability, we performed the clinical trials and we were capable of doing the PD-L1 testing when other people were not. And so that’s what happened to us. As a result of good work that we did in pharma services, but not because of a lot of sales effort.

Okay. And just so then when you think about what the sales, of course, is doing on a day-to-day basis, maybe you could just give a little more detail around what exactly obviously I understand what you are saying when you are saying focus on retention, but how does that preclude growth is that they are not in the offices everyday, they are talking to different people in the office, I am just trying to get a sense of why, why they aren’t – why there isn’t also incremental growth given the touch points between sales and the customer, I guess?

Yes, that’s a good question, Amanda. So let me try to shed some context for it here. So – ours – we have a very good sales team and a very experienced sales team. They are out in the field a lot. They are not in the offices. What they are doing with clients and have done for the last 6 months is train a lot of clients about the use of a relatively new system or a different system for those clients and to train them on new ordering forms and new contacts. There is a variety of training needs that we have put our clients through, as we have changed from one system to another. In addition, there has been a lot of training on new products, because the NeoGenomics process was as you know, we have a very large molecular menu and Clarient has a very large immunohistochemistry menus, there is a lot of training that has occurred as a result of that. As clients move, our sales team is in the office trying to help them navigate through new – translating that training into actual practice. And so they have spent a lot of time doing that and that’s been why we haven’t spent a lot of time in our normal selling activities.

Got it, okay. And then I just had one follow-up on the ASP side, so it sounds like, I was going to ask you what the ASP decline would have been without PD-L1, I think you said it was the most of it, is that right, so I was going to see if you would like to give us a quantification there?

Not just PD-L1, it’s molecular too…

Yes.

Since we grow at an outsize rate. And molecular, we still do a lot of single marker single molecular tests which are relative low reimbursement tests relative to the overall corporate average. And so there are some of those two where most of the compression in AUP reduction. And in fact there will be most of the compression in AUP reduction that we are projecting on a full year basis this year.

Yes. And I guess my last one is going to be and I don’t know how much too far you are willing to go here, but I think it might be helpful to just kind of remind us the various segments, so you just mentioned molecular, a lot of that is single genes, but you are doing some canal there, so I guess it seems to me that at least molecular ASP might increase over time and then you got the rest of the business and then obviously, PD-L1 being a detractor of ASP, so can you just kind of go back and give us a high level of various businesses, the various ASPs and maybe kind of how you expect to try and [Technical Difficulty]?

So our overall corporate average, molecular average revenue per test in quarter four was about $320.

Okay.

That is a blend of those panels which were accounted as one test and the single marker test. It has been trending up slightly over sequentially in the last three or four quarters because we are doing more and more panels. But at the end of the day, the volumes, the majority of our testing is still the single marker molecular stuff. It’s not the case where the panels are the biggest piece of it. It’s the run of the oat mill JAK2, KRAS, EGFRs and whatnot. The IHC test that we do have an overall corporate average of around $167, however that has actually been trending down, because PD-L1 is only about $100 test, one antibody that we do an IHC test. So we actually saw a pretty substantial compression from Q3 to Q4. And that’s been kind of working the other way as well. We don’t really get into a lot of detail on giving our average revenue per test on the other stuff, because we are 58% client bill and it tends to give the roadmap for our competitors on where the pricing. We are going to demure on any further details at this point.

Okay, very helpful. Thank you.

Our next question comes from the line of Drew Jones of Stephens. Please proceed with your question.

Hi. Good morning guys.

Good morning.

I just want to make sure I have my arms around where we stand on synergy recognition, so could you give us a little bit better idea about what was actually realized in 2016, I guess how much of the synergy you are going to be come about as a result of the Aliso Viejo lab combination. And then Steve, you talked a little bit about second half of this year that $7 million to $8 million recognition, is that – should we split that by two and that’s basically $3.5 million to $4 million per quarter recognition?

Well, first, I would like to ask George to sort of address what we have realized and what we expect to realize this year and we can talk about the timing.

Sure. Yes. In terms of – obviously you see the reductions in our cost per test in 2016. We have had very significant benefits. Obviously, the sales teams were combined in the first quarter. That was a significant synergy. Clarient sent out about $4 million of testing a year to various other laboratories, so vast, vast majority of that testing has been brought in-house now and we are testing it in the NeoGenomics molecular lab, most of that is molecular. So that was a significant synergy gain. And what we were able to combine some contracts on the laboratory side, but if you think about it, the real significant benefit comes from bringing the two laboratories together, being able to one batch in the wet lab areas rather than two separate laboratories, that’s really where the significant gain is going to come. So as Doug mentioned, the two labs are coming together in late March. So we expect $7 million, $8 million to be realized this year. Obviously, if we come together at the end of the first quarter, clearly there will be a tail that will go about into 2018. So we still believe in the original synergy numbers just the timing and sort of the phasing of that. But you should still think $7 million or $8 million in terms of total synergies for 2017.

And that translates somewhere on the order of, call it a 6% area cost per test this year. We hope we can do better than that, our internal targets are always better than that. Yes, it does get a little funky. How much of your cost per test increase, do you attribute to synergies versus just scale and just give us a little license on that and call it all synergies those numbers to hold out.

Okay. And then the pharma services business, obviously long-term outlook there very good, but with the backlog, what percentage do you expect to recognize over the next 12 months and should that lumpiness may be we get a little bit of a snapback in the first half of this year or is that more of a second half event as well?

So we don’t actually breakout biopharma revenue projections. We do expect to see good growth in this year, but I can’t really get answering that question about how much we expect this year, because as you get at your what percentage of the backlog. Generally, we expect growth in the biopharma higher than the overall corporate average growth rate. And as to the lumpiness Doug, do you want to address that one?

Yes. Let me just say one thing that each of these projects in the backlog have different terms. I mean some of these projects would be realized over three months and some over 3 years. I would say also that the growth we reported about 85% growth from the beginning of 2016 to the end of 2016 in the backlog, a lot of that growth came in the second half of 2016. Once a project is signed, putting the backlog, there is a whole timeline that’s required for that revenue begins to be realized. That timeline can stretch from three months to six months, as patients are recruited in the clinical trials and that process moves along. So we would expect that the revenue for pharma services is going to be a little bit back end loaded in 2017, but we are pretty bullish about it.

Thanks guys.

Thank you.

Our next question comes from the line of Paul Knight of Janney Montgomery Scott. Please proceed with your question.

Hi Doug and Steve, could you talk about your test volume growth outlook on your 2017 guidance for both Clarient and core NeoGenomics?

So the midpoint of our guidance approximately suggest somewhere on the order of 15% full year volume growth. As I mentioned in my remarks, you should assume somewhere in the order of $355 to $360 average revenue per test on a full year basis this year. We would just model it as flat for now.

Okay. And then as we think about a multi-year model, will you become a taxpayer, should we think about a tax rate in our years for NeoGenomics?

Yes. You see the book tax rate, I mean typically there were some unusual items in the fourth quarter with the impairments and the like. But for the first half of the year, we ran 45% to 50% that would be our more typical book tax rate going forward. Keep in mind though that we do have NOLs and we are not expecting to be a taxpayer for 2017 and actually for probably 2018 as well.

Okay. And then lastly, the Switzerland facility doesn’t come online when and when do we expect revenue from it, Doug? And last on the contract research business, the $37 million of backlog does that get burn off over what a couple of years. What is the burn profile on it?

Paul, George will answer the Geneva question and I will take the backlog.

Yes, we have submitted applications for tax holidays in two cantons in the Geneva area. So obviously, we are hopeful to receive the tax holiday, which would obviously be very significant to have us in terms of investing. Our plan, certainly, is to bring the laboratory up. Again, we have got the expertise here. So, we think once we have the site identified literally in 3, 4 months, we can get some of these testing platforms up with assistance from U.S. people going over as well as a scenario, where we think there is quite a bit of talent already. So, our goal certainly is to get it up and running by the third quarter and hopefully having it contribute into our revenue growth by being able to place European-based study out in Q3 and Q4.

Well, let me try to address your question around backlog and how that relates to revenue. The backlog will burn over a variety of time periods. It’s a lot of different kinds of projects. I think the best way to answer your question is to suggest that we are looking for revenue growth in pharma in 2017 of about 20% plus versus 2016. So, that will give you a sense for how it’s going to burn and there will be some projects that aren’t in our backlog that will begin to realize revenue for in 2017 as well, but I think that will give you some sense for it.

Okay, thank you.

Our next question comes from the line of Chris Lewis of ROTH Capital Partners. Please proceed with your question.

Hey, guys. Good morning. Thanks for taking the questions. I wanted to start on the LIS migration process. Doug, I was hoping you could just elaborate on the strategies you’ve put in place to help address some of those concerns, you talked about with the dissatisfied customers to ensure you don’t lose additional clients going forward?

Yes, Chris. Thanks for the question. As I said, the testing process was not where we have had challenges. We have had challenges and I think I mentioned a couple of different areas. Order entry, which we call accessioning in the lab business, is a key one, logistics is another one. In order entry for example, we have got – as people – as our clients were moving to one system from two systems, we had people in accessioning working actually in two different laboratory systems. So, some specimens would come in, they put the orders in the old Clarient system. Some specimens came in, they put the orders in the NeoGenomic system. The NeoGenomic system was different than the Clarient system. So, these accessioners, these people who are putting the orders in have to be trained on both systems, because they are different and because they are moving from system to system, they make some errors. When they make errors, what happens is we might put the client name in wrong or put the address in wrong or something like that. These things cause issues. And then when that happens, then there is a problem hold and we don’t get test output on time or we have to callback the client. And we have had those kinds of issues. You might say well, that’s really easy to fix. Well, it is easy to fix, but it just takes a little time, because we have to bring in the right people, we have to train them, we have to make sure that we have the right quality controls. We do a whole number of things and we put spot teams on this. We have operations excellence group that is very, very involved and we are getting these things fixed, but it takes a little time. And there are – as you know, this business, there are 500 things that have to happen every single day to satisfy our client. And you can do – ordered 99 of them very well and you make one mistake and it’s a mistake. So, I feel very confident that we will get all of these issues well under management and the lab in balance, but it’s just taking a little bit longer than we expected.

Understand. And then the 16% pro forma clinical genetic testing growth, do you happen to have a breakout between the legacy Neo and Clarient segments in the quarter?

We don’t, because we have now completely integrated Clarient and NeoGenomics clients. They are all on the same system. We could with a very, very deep analysis, but we don’t – they are all on the same system now. It’s very, very difficult for us to break them down.

And in terms of cross-selling, it sounds like you still really haven’t fully realized the cross-selling opportunities yet with the LIS migration and menu now aligned. When do you expect we could start to see some increased cross-selling opportunities?

You are right. We have not yet had a lot of cross-selling going on. We have about 4 weeks left or 5 weeks left before we have the labs put together. And as soon as that happens, we will have a little bit more capacity and room and we will have the ability and confidence to go out and really cross-sell as we have got a terrific and deep product mix and a very good service offering at our sales representatives, you just can’t wait to be able to cross-sell.

Got it. And just one more from me, what’s the expected interest expense for 2017? Thanks.

Well, I am going to give you a number and tell you that we believe it’s reasonably good, but I think you need to give us a little leeway. But approximately $5.4 million for the full year would be just a pure interest expense on the debt. Obviously that will be impacted by how much lease financing we do. We have been generally replacing leases that run off with new leases. So, I don’t know that, that will vary too much.

Okay, thanks for the time.

Thanks, Chris.

Our next question comes from the line of Raymond Myers of Benchmark. Please proceed with your question.

Yes, thank you. First question is could you tell us what the revenue was for PD-L1 in the quarter?

No, we didn’t disclose that right.

Would you or you will?

We don’t typically give out revenue by any one product line. And it gets great smack at competitive issues and dynamics.

Okay. Why was it that the second half of the migration was tougher or somehow different than in the first half that had gone so well, I am just curious kind of what was the difference and what did you learn from that?

I think the second half, Ray, was a little tougher, because we had so many of this larger clients migrating at the same time. And this was an execution – we didn’t execute this very well, I will accept. And the clients that migrated sort of in November and December, a lot of them were from California. And they have their own requirements and some of those requirements where they come in at a certain hour for their overnight order entry, there are whole number of issues that put a little more stress on certain departments as opposed to having more of a streamlined smooth approach, where we are increasing the volume at all departments on an equal basis. So, we had an anomaly in volume growth in certain areas that stressed certain departments and had it to do over again, we would have smoothed some of those client migration activities earlier in the year.

Okay, thank you. And do you feel you have your arms around those issues now or are you still working them out?

Yes, we have our arms around the issues and we are working them out.

Okay, excellent. And turning to the billing issue, was the billing issue resolved now or same question, are you still working that out?

No. We are seeing progress, but again exactly the same is accessioning when we changed from one system to the other, there was an initial dip in productivity. Though the productivity has come up in January, generally we were able to get what was build out, what came to the lab able to be build out, but in terms of working the backlog down, that’s something that’s happening now. We are starting to see that come down in February and expect that to come down in March. But realize there is a DSO lag, so when you catch up on that backlog in February and March, you are not going to see that cash billing until later in the Q2.

Okay, thanks. And let me just clarify on the billing, there is different shades of billing issues, is it the type of billing issue where it’s just difficult to get the bills entered into the appropriate systems in the necessary format or is it a billing problem where there is a risk where you may not get paid?

No. It’s just a matter of us processing the volumes and the fact that we had a dip in productivity, because the people learning the new system. So it really is just a lag of getting through the claims and making up for the weeks and we had that productivity dip as people went from literally billing a 100 to billing 40. So we lost that productivity gap and basically, now we have to catch it up. It really doesn’t affect the quality of the claim. It’s just a matter of working through those. And even our shortest claim filing deadline is 90 days and we are well within any limits like that.

Okay, good, that’s helpful. And then finally, just maybe Doug, could you give us a sense of what confidence or disability, do you have in restoring the historical growth levels and service levels of the business throughout this year?

We have very high confidence that we will restore the kind of exceptional service that NeoGenomics is accustomed to delivering. In terms of growth, I think all of the growth projections that we have made to you, we stand behind. We have got a couple of quarters here, where we have got to resume and re-prime the pump, so to say. But we are confident in our same growth projections that we have provided in the past.

Okay, it sounds good and we will see you in May.

Thank you.

Our next question comes from the line of Bryan Brokmeier of Cantor Fitzgerald. Please proceed with your question.

Hi, good morning. Is there anything materially different in the reasons behind the lost clients in the fourth quarter or the tone relate to you compared to the client you had previously lost and that you have gotten back?

I don’t think so. I mean I think that it all comes down to service. And if a client recognizes that we are delivering and are capable of continuing to deliver a very strong service, we will generally keep that client. We have very good client relationships. I think people are willing to be patient with us. If we have a turnaround time, which may slip a bit, because generally our turnaround times leave the industry, but we have got to make sure that we treat our clients well that they know that they are valuable to us and that we get our service back in line with what they expect and we intend that we are delivering that for the most part today. And we have got a few outliers that we have got pay our attention to.

Okay. And you announced $150 million credit facility at the end of December. You still have dry powder for M&A for repurchasing the remaining preferred shares and you guys discount on the repurchase of those preferred before the end of the year, so should we expect that you most likely use your cash flow and the remaining revolver for those shares later this year or how should we think about your capital deployment plans?

You can think about it that we are going to make decisions, which are based on the economics. So right now, we are in the market, looking at opportunities to grow our business both organically and through M&A. And if we are presented and are able to negotiate some deals that makes sense to us, we will deploy our capital in that way. We know what the recurrent is that we deploy our capital to redeem the remaining preferred stock and that’s sort of a benchmark for us to work against.

Okay. And Path Logic continues to be a little bit drag in the business, have you given any consideration to divesting it?

Yes. Path Logic’s performance has not met our expectations and we are evaluating all of our strategic alternatives. And we would expect to be able to provide more clarity on that over the next few quarters.

Okay. And lastly, given the revolver that you have in place and what level of cash are you comfortable addressing down to, as you engage in M&A or repurchase those shares?

Yes. I think if you look at our balance sheet as of December, that’s probably about the cash balance you should expect to see on our book. But I think obviously, we don’t want take it completely down, so we do have – we want to have some dry powder and I think that’s the level you should expect going forward.

Okay. Thanks a lot.

Thank you.

Thank you.

Our next question comes from the line of Joe Munda of First Analysis. Please proceed with your question.

Good morning, can you hear me, okay.

Yes.

Couple of questions, just piggybacking off some of the client migration questions Doug, can you let us know, what – how many clients actually were migrated in the fourth quarter?

Yes. We – let me describe larger clients. So we migrated in total about 2,500 clients. I would say that about half of the larger clients migrated prior to November and December and about half migrated in November and December.

Okay. Can you give us a ballpark of how many larger clients you guys have, I mean…?

We struggled a little bit with this because we haven’t previously disclosed how we describe clients, but I would say that we migrated about 700 of the “larger clients” in November and December.

Okay, that’s helpful. As far as the facility in Switzerland, you guys talk about opening in third quarter ‘17, I am just wondering does the guidance reflect revenue contributions from that facility in 2017 or is there upside there?

There may be upside there. We try to be conservative in that. We reported the backlog of I think $37 million for pharma services. I don’t believe that there is any backlog in there for international trials or projects. So if we were to book some, that would go into backlog and we will see how quickly we can realize it.

Okay, that’s helpful. And then I guess looking forward on that facility, could that facility essentially accelerate biopharma growth above the 20% Doug, you talked about in as far as growth is concerned in 2017?

Yes, it might.

Okay. And then I guess Steve, on CapEx and headcount related to that facility, can you give us some sense of what that would look like?

I think our expectation initially is in the $2 million ballpark. Again, it’s not going to be a large facility. We are probably talking to all the 15 people to start. And then clearly the revenue and the contract wins will drive ultimately how much we grow. But that will be happy problem to have, if we have so much business, we have to put more capital into it.

Okay. And then as far as Path Logic is concerned, you guys recognize an impairment charge there in the fourth quarter, can we – are we assuming further impairment charges, as we move through 2017 or do you think we have seen the last one?

We took a charge to write-off the remaining intangible value that we assigned the customer list, when we did the acquisition. So that’s it.

Okay. And then I guess my last question more of a macro picture year, new administration coming in, Tom Price, HSS Secretary, I was just wondering, I wanted to get your take on what you guys feel expectation wise going forward, do you feel confident about diagnostic tests and particularly in the oncology space, any interactions early on would be great?

Okay. Thanks for the question about that. I think generally, we are pleased that the current administration is one in which that – we are regulated heavily. And I think the current administration, obviously has announced that they are going to kind of roll back some of the regulations. There are two that affect our industry a lot. One is the so-called LDT proposed guidance. This is our laboratory developed test guidance that the FDA proposed to regulate over the last few years. As a result of the new administration primarily the FDA decided that they were not going to finalize that guidance. That doesn’t mean that the guidance has been withdrawn. There is a difference. It’s – they have decided, they have to finalize it. I think that Congress is probably more support of than they have been in the past of potentially a legislative solution to the LDT issue. And I think the industry is going to try to figure out whether we should pursue a legislative solution rather than to just allow the FDA to propose something and we can work collaboratively with the legislature and the FDA. In terms of – the other big item is called PAMA. And PAMA is a way to instill some market based pricing in the clinical lab fee schedule. And that legislation is proceeding at the current pace of implementation in 2018. I would remark that the clinical lab fee schedule change only applies to NeoGenomics in two different test types. One is molecular and the other is cytogenetics. And as a result we don’t expect that PAMA implementation will greatly affect NeoGenomics. I think just for information, there is a sense in the industry that PAMA is not broad enough in its definition of what laboratories should provide these data. Right now, only about 5% of laboratories are submitting private payer data to CMS and the industry believes that that’s insufficient and there should be a broader collection of data to get the true market based measure. So that dialogue will continue, I expect. And we will see what happens as a result. But there is – I think the industry is encouraged that we may be able to have better dialogues about these important matters facing the industry.

Okay. Thank you.

You’re welcome.

Our next question comes from the line of Bill Bonello of Craig-Hallum. Please proceed with your question.

Hi. Thanks guys. Thanks for taking all these questions. Just this is short-term focus, but just to make sure we don’t run into problems unnecessarily, the Q1 revenue and EBITDA consensus that’s out, there is $65 million and $10.5 million for EBITDA, it just strikes me that there is one less day in the quarter, you are still working through the lab integration, those feel like they might be a little bit on the high side, I am wondering if we should think of the quarter as being maybe more flat sequentially from revenue and EBITDA basis and then progressing throughout the year, I guess kind of forcing you into Q1 guidance, if you give it or at least parameters?

We appreciate the question, Bill. Well, we don’t typically give forward quarter guidance, I think it does warrant giving a little bit more color on this right now. We do expect the growth this year to be sort of back end biased. In Q1, we think analysts would be sort of well served by setting up their models with just minimal growth, maybe in the $61 million to $62 million revenue range and certainly EBITDA, if you are not doing $65 million of revenue, EBITDA probably need to come down into 7.5 to maybe 8.5 range at the most. And I think if the analysts reset their Q1 around those levels and then kind of project from there on the full year guidance, we will get close to being in the right zip code for everybody.

Perfect, that’s very helpful. And then just because I have you, I am going to try one more time to questions – a question earlier on the synergies and I know it’s imprecise, but as we are thinking about the growth opportunity, I mean how much of the $24 million to $30 million of synergies is probably still ahead of us in terms of looking at where we are at today and then sort of layering on incremental EBITDA?

So when you talk about synergies Bill, you really have to look at what’s realized in the period and then what the run rate is at the end of the period. So we have stated last year that we expected to do $6 million to $8 million and sort of generally hinted we are at the midpoint or better of that. We just did it in our remarks this year that we expect to realize another $8 or so million this year, so let’s call that $15 million of the total will be utilized or in the mix, if you will, by the end of this year. However, in Q4 of this year, we will be on a much higher run rate from those. As to whether we are on a run rate that do the full 24 to 30 or not, that sort of remains to be seen and will have to give us a little bit of room on that. But we do believe that it’s only going to take few quarters of operating the labs and the combined facilities off a one laboratory information system and one billing system to begin to unlock meaningful synergies.

Okay, perfect. And those are – when you talk about those synergies, I mean those are truly you think of those as truly incremental to just the normal EBITDA growth you would get from revenue growth in normal leverage?

So again, it gets hard to separate out what’s the synergy and what’s the benefit of scale. I mean they are almost one and the same, because we had so much scale. If you just think about somewhere on the order of 5%, 6% cost per test reductions, that would get you to around $7 million to $8 million of cost reductions on just the clinical genetics side. Now, there will be some other stuff that shows up in G&A as well, but we are also making investments. We are making investments in Switzerland and whatnot. So it gets hard to really get too precise on all of this stuff, but we think the bulk of the synergies will come in the cost of goods sold line item, as we continue to unlock the benefits of having it write on the same system and in the same facility. George, do you want to add anything to that?

Yes. Bill, I would add just one quick comment. Let me give you an example of what Steve was talking about. So we are applying supplies agreements that Clarient had and methodologies that Clarient had to some NeoGenomics processes. Now we have eventually figured out a better way to reduce cost probably, but because we have these processes and we understand them, we are getting $2 million, $3 million, $4 million of synergies just as a result of that. And so I think that we can stand up and say the synergies that we talked about are very real as a result of this deal. And I think we are on track with accomplishing the synergy projections that we talked about.

Okay, that’s helpful. I mean the reason just you understand the reason I was asking is more about thinking about modeling long-term, I mean I think there is a tendency for both investors and analysts to put some basic level of EBITDA growth and then they want – we want to layer an incremental $15 million of synergy on top of that or whatever and it sounds like from what you are saying, that might be a bit aggressive if we did sort of both growth and layered in that complete synergy on top of it, some of the synergy and growth are redundant?

Yes. I think you just took where we finished last year, $34.7 million of EBITDA and took the midpoint of our EBITDA guidance this year – 32% EBITDA growth, which moving into 2018 EBITDA growth should be higher than the revenue growth, but again, whether it will be another 32% or not remains to be seen. But certainly, as we unlock synergies on a full run rate basis by the Q4 ‘17, a lot of that is going to accrue to EBITDA improvements in 2018 and without given any out your guidance yet, but certainly EBITDA growth in excess of revenue growth and probably meaningfully in excess of revenue growth is not about assumption for 2018.

Yes. Great. Thank you.

Okay. Thank you, everyone. So as we end call here, I want to recognize the 969 NeoGenomics team members around the country for their dedication and commitment to building a world-class cancer genetics testing program. And on behalf of the whole team, I want to thank all of our investors and analysts for your time in joining us this morning for our fourth quarter 2016 earnings call. And let you know that our first quarter 2017 earnings call will be held on or around April 26 of this year. For those listening that are investors or are considering an investment in NeoGenomics, we thank you very much for your interest in our company. Goodbye.

This concludes today’s conference. Thanks for your participation. You may disconnect your lines at this time.